Natalia Vélez-Tirado

Natalia Vélez-Tirado

Auto-generated profile, based on publicly available information

Natalia Vélez-Tirado

Pediatric Allergy and Clinical Immunology HOMI Hospital Pediátrico la Misericordia Bogotá Colombia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2018 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
ADAngela Deyà‐Martínez
Angela Deyà‐Martínez
ASAna Esteve Solé
Ana Esteve Solé
NVNatalia Vélez‐Tirado
Natalia Vélez‐Tirado
VCVeronica Celis
Veronica Celis
JCJordi Costa
Jordi Costa
LALaia Alsina
Laia Alsina

29 December 2021 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NVNatalia Velez‐Tirado
Natalia Velez‐Tirado
MYMarco Antonio Yamazaki‐Nakashimada
Marco Antonio Yamazaki‐Nakashimada
EVEnrique Lopez Valentín
Enrique Lopez Valentín
APArmando Partida‐Gaytan
Armando Partida‐Gaytan
SSSelma C. Scheffler‐Mendoza
Selma C. Scheffler‐Mendoza
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes

29 July 2023 in Pediatric Dermatology
Verified
Journal Article
Closed access
PGPaula A. Gutierrez‐Marin
Paula A. Gutierrez‐Marin
LCLina M. Castano‐Jaramillo
Lina M. Castano‐Jaramillo
NVNatalia Velez‐Tirado
Natalia Velez‐Tirado
MVMilena Villamil‐Osorio
Milena Villamil‐Osorio
EPEsteban Patiño
Esteban Patiño
MHMaribel Trujillo Hernandez
Maribel Trujillo Hernandez

7 August 2019 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
NVNatalia Velez-Tirado
Natalia Velez-Tirado
CRCecilia Ridaura-Sanz
Cecilia Ridaura-Sanz
EVEdna Venegas-Montoya
Edna Venegas-Montoya
SSSelma Scheffler-Mendoza
Selma Scheffler-Mendoza
RCRosalinda Camacho-Moreno
Rosalinda Camacho-Moreno
MNMarco Antonio Yamazaki Nakashimada
Marco Antonio Yamazaki Nakashimada

31 March 2024 in Biomédica
Verified
Journal Article
Open access
PDF file
NVNatalia Vélez-Tirado
Natalia Vélez-Tirado
LCLina Castaño-Jaramillo
Lina Castaño-Jaramillo
SRSonia M Restrepo-Gualteros
Sonia M Restrepo-Gualteros
CACatalina Alcalá-Lozano
Catalina Alcalá-Lozano
ERErika Ruge
Erika Ruge
CGCamacho-Moreno Germán
Camacho-Moreno Germán
Introduction. During the SARS-CoV-2 pandemic, many countries experienced decreased respiratory virus circulation, followed by an out-of-season outbreak. In a pediatric hospital in Colombia, we observed a surge in severe adenovirus infections, leading to concerns about the impact of eased public health restrictions and immune debt in children under five years old.Objective. To describe the clinical characteristics of patients with severe adenovirus infection in a pediatric hospital in Colombia.Materials and methods. We reviewed the data of 227 patients with severe adenovirus infection at the Fundación Hospital Pediátrico La Misericordia.Results. A total of 196 patients were included in this study. The median age was two years, and 62% were male. Adenoviruses were isolated from all patients’ samples. Ninetyseven percent were admitted to the pediatric intensive care unit, 94% required respiratory support, and the in-hospital lethality rate was 11%.Conclusion. In 2022, there was an outbreak of severe adenovirus infections, affecting mainly children under five years of age, with higher-than-usual mortality.

1 November 2019 in Lupus
Verified
Journal Article
Closed access
PDF file
IAI Aguirre-Martinez
I Aguirre-Martinez
NVN Vélez-Tirado
N Vélez-Tirado
MGMaria Teresa García-Romero
Maria Teresa García-Romero
ARA L Rodríguez-Lozano
A L Rodríguez-Lozano
CCC T Corcuera-Delgado
C T Corcuera-Delgado
FRF Rivas-Larrauri
F Rivas-Larrauri
Rowell syndrome (RS) is a rare disease characterized by the association of systemic lupus erythematosus (SLE) or cutaneous lupus with lesions similar to erythema multiforme and the presence of autoantibodies including ANA, SSA, SSB, or rheumatoid factor. Due to the low incidence of this disease, the epidemiology of RS is not clear. So far there are 95 cases reported in the literature; of these, only seven cases are pediatric patients. Macrophage activation syndrome (MAS) is an increasingly recognized complication of SLE, although its true prevalence in childhood is still unknown. We describe a unique pediatric patient with RS who developed MAS.